Clinical trials
catalyst calendar across sponsors →Studies where VKTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 1 with posted results
Held by 16 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +11 more) · FINRA short interest 10.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383Percent change in body weight from baseline to Week 78 in body weightRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: VK2735 | Weight Loss | 1,100 | 2027-07-01 | in 315 d | 2026-04-07 |
| VK2735 for Weight Management Phase 3NCT07104500Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatmentRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: VK2735 | Weight Loss | 4,500 | 2027-07-01 | in 315 d | 2025-11-24 |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055Percent (relative) change from baseline in body weight after 13 weeks of treatmentRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, VK2735 | Weight Loss | 280 | 2025-06-24actual | — | 2025-10-06 |
| Phase 1 Study to Evaluate the Safety and Tolerability of VK2735NCT05203237Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Biological: VK2735, Placebo · Drug: VK2735 Placebo, VK2735 Drug | Weight Loss, NASH | 92 | 2024-11-04actual | — | 2025-02-17 |
| A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMNNCT04973657Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)Randomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: VK0214 · Other: Placebo | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | 24 | 2024-10-09actual | — | 2025-02-17 |
| VK2735 for Weight Management Phase 2NCT06068946Percent (relative) change from baseline to Week 13 in body weightRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: VK2735, Placebo | Weight Loss | 176 | 2024-02-27actual | — | 2025-02-12 |
| A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHNCT04173065Liver FatRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: VK2809, Placebos | NASH - Nonalcoholic Steatohepatitis | 248 | 2023-05-15actual | — | 2024-06-14 |
| Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver DiseaseNCT02927184Change in LDL-C in patients receiving VK2809 compared to placeboRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: VK2809, Placebo | Hyperlipidemia, NAFLD | 59 | 2019-03-26actual | — | 2021-04-26 |
| Acute Hip Fracture Study in Patients 65 Years or GreaterNCT02578095results2025-12-29Efficacy in Hip Fracture Patients Confirmed by DXA Scan.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: VK5211, Placebo | Hip Fractures | 108 | 2017-11-15actual | — | 2025-12-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19